BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...She succeeds CFO Michael Ostrach, who is retiring after 14 years and will remain with the vaccine company...
BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

...announced in September, returned as acting CFO potentially until mid-2021 to support strategic planning and the vaccine company’s...
BioCentury | Dec 30, 2020
Product Development

2020’s silver linings, New Year’s hopes: a BioCentury podcast

Unprecedented industry collaboration topped the “Best of 2020” list for BioCentury’s editorial team for a year in which there was no question what topped the “Worst” list. On the latest edition of...
BioCentury | Sep 22, 2020
Politics, Policy & Law

Azar’s memo & biotech’s deals: a BioCentury podcast

A controversy over a memo from HHS Secretary Alex Azar has further exposed the fraught atmosphere in Washington over claims that FDA and other agencies have been politicized amid the global pandemic. In the latest BioCentury This...
BioCentury | Aug 11, 2020
Product Development

BIOEquality, data sharing and deals: a BioCentury podcast

BIO is calling on biopharmaceutical companies to put their pledges on social justice into practice as the trade group launches an initiative that aims to diversify the biotech workforce and ensure that...
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Angus Grant as chief business executive, a new position at the cancer company. He was CEO of the Dementia Discovery Fund. After eight years with Sarepta Therapeutics Inc. (NASDAQ:SRPT), EVP,...
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

Novavax Inc. (NASDAQ:NVAX), which expects Phase I data for its COVID-19 vaccine in July, hired Filip Dubovsky as SVP and CMO. He succeeds CMO Louis Fries, who has retired. Dubovsky was head of clinical engagement...
BioCentury | Jun 13, 2020
Finance

With nearly $1B raised overnight, quartet of offerings underscore demand for biotech IPOs

Five biopharma IPOs raised nearly $1 billion this week, with four of the companies each raising more than $200 million and trading up at least 30% in their first day of trading. The strong debuts...
BioCentury | Jun 9, 2020
Finance

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

Following last week’s IPO market performance, which saw three biotechs raise more than $740 million, a trio of preclinical companies are now preparing for their at bat. The IPO queue also gained five more companies...
BioCentury | May 6, 2020
Management Tracks

Mendel named GenMark’s CEO; plus SutroVax, Illumina, Arrowhead, Tessa and more

GenMark Diagnostics Inc. (NASDAQ:GNMK) said interim president and CEO Scott Mendel will now serve in those roles full-time. He joined the company as CFO in 2014 and became COO in 2019. The diagnostic company’s PCR-based...
Items per page:
1 - 10 of 65
BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...She succeeds CFO Michael Ostrach, who is retiring after 14 years and will remain with the vaccine company...
BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

...announced in September, returned as acting CFO potentially until mid-2021 to support strategic planning and the vaccine company’s...
BioCentury | Dec 30, 2020
Product Development

2020’s silver linings, New Year’s hopes: a BioCentury podcast

Unprecedented industry collaboration topped the “Best of 2020” list for BioCentury’s editorial team for a year in which there was no question what topped the “Worst” list. On the latest edition of...
BioCentury | Sep 22, 2020
Politics, Policy & Law

Azar’s memo & biotech’s deals: a BioCentury podcast

A controversy over a memo from HHS Secretary Alex Azar has further exposed the fraught atmosphere in Washington over claims that FDA and other agencies have been politicized amid the global pandemic. In the latest BioCentury This...
BioCentury | Aug 11, 2020
Product Development

BIOEquality, data sharing and deals: a BioCentury podcast

BIO is calling on biopharmaceutical companies to put their pledges on social justice into practice as the trade group launches an initiative that aims to diversify the biotech workforce and ensure that...
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Angus Grant as chief business executive, a new position at the cancer company. He was CEO of the Dementia Discovery Fund. After eight years with Sarepta Therapeutics Inc. (NASDAQ:SRPT), EVP,...
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

Novavax Inc. (NASDAQ:NVAX), which expects Phase I data for its COVID-19 vaccine in July, hired Filip Dubovsky as SVP and CMO. He succeeds CMO Louis Fries, who has retired. Dubovsky was head of clinical engagement...
BioCentury | Jun 13, 2020
Finance

With nearly $1B raised overnight, quartet of offerings underscore demand for biotech IPOs

Five biopharma IPOs raised nearly $1 billion this week, with four of the companies each raising more than $200 million and trading up at least 30% in their first day of trading. The strong debuts...
BioCentury | Jun 9, 2020
Finance

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

Following last week’s IPO market performance, which saw three biotechs raise more than $740 million, a trio of preclinical companies are now preparing for their at bat. The IPO queue also gained five more companies...
BioCentury | May 6, 2020
Management Tracks

Mendel named GenMark’s CEO; plus SutroVax, Illumina, Arrowhead, Tessa and more

GenMark Diagnostics Inc. (NASDAQ:GNMK) said interim president and CEO Scott Mendel will now serve in those roles full-time. He joined the company as CFO in 2014 and became COO in 2019. The diagnostic company’s PCR-based...
Items per page:
1 - 10 of 65